Education
About Us
Working with TipRanks
Follow Us
Percheron Therapeutics (AU:PER)
ASX:PER
PER Stock Chart & Stats
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.14
Previous CloseN/A
Volume20.44M
Average Volume (3M)2.31M
Market Cap
$8.70M
Enterprise Value-AU$13.28M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Aug 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,087,437,600
10 Day Avg. Volume3,345,860
30 Day Avg. Volume2,306,555
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.53
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$0.02Price Target Upside57.91% Upside
Rating ConsensusHold
Number of Analyst Covering0
Percheron Therapeutics News
PER FAQ
What was Percheron Therapeutics’s price range in the past 12 months?
Percheron Therapeutics lowest share price was <AU$0.01 and its highest was AU$0.14 in the past 12 months.
What is Percheron Therapeutics’s market cap?
Percheron Therapeutics’s market cap is $8.70M.
When is Percheron Therapeutics’s upcoming earnings report date?
Percheron Therapeutics’s upcoming earnings report date is Aug 27, 2025 which is in 19 days.
How were Percheron Therapeutics’s earnings last quarter?
Percheron Therapeutics released its earnings results on Feb 19, 2025. The company reported -AU$0.009 earnings per share for the quarter, beating the consensus estimate of -AU$0.015 by AU$0.006.
Is Percheron Therapeutics overvalued?
According to Wall Street analysts Percheron Therapeutics’s price is currently Undervalued.
Does Percheron Therapeutics pay dividends?
Percheron Therapeutics does not currently pay dividends.
What is Percheron Therapeutics’s EPS estimate?
Percheron Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Percheron Therapeutics have?
Percheron Therapeutics has 1,087,437,600 shares outstanding.
What happened to Percheron Therapeutics’s price movement after its last earnings report?
Percheron Therapeutics reported an EPS of -AU$0.009 in its last earnings report, beating expectations of -AU$0.015. Following the earnings report the stock price went up 2.439%.
Which hedge fund is a major shareholder of Percheron Therapeutics?
Currently, no hedge funds are holding shares in AU:PER
Percheron Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.02 (57.91% Upside)
$0.02 (57.91% Upside)
Blogger Sentiment
Bullish
AU:PER Sentiment 77%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $16.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
58.33%
12-Months-Change
Fundamentals
Return on Equity
-100.19%
Trailing 12-Months
Asset Growth
-18.60%
Trailing 12-Months
Company Description
Percheron Therapeutics
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its product pipeline also includes Atesidorsen (ATL1103), an oligonucleotide targeting growth hormone receptor designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. Percheron Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Ownership Overview
10.20% Insiders
―
Mutual Funds
― Other Institutional Investors
89.80% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---